Treatment of metastatic extramammary paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F

Oncologist

Volumn 19, Issue 9, 2014, Pages

  Vornicova, Olga ^a   Hershkovitz, Dov ^a   Yablonski Peretz, Tamar ^b   Ben Itzhak, Ofer ^a   Keidar, Zohar ^a   Bar Sela, Gil ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; ERBB2 PROTEIN, HUMAN;

ADNEXA DISEASE; AGED; BIOPSY; BONE METASTASIS; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENE MUTATION; HUMAN; HUMAN TISSUE; LOW BACK PAIN; MALE; MULTIPLE CYCLE TREATMENT; NOTE; PAGET SKIN DISEASE; TREATMENT RESPONSE; ADENOCARCINOMA; ADNEXAL DISEASES; ANTAGONISTS AND INHIBITORS; COMPLICATION; FEMALE; GENETICS; HUMAN GENOME; METASTASIS; MOLECULARLY TARGETED THERAPY; MUTATION; PAGET DISEASE, EXTRAMAMMARY; PATHOLOGY;

ADENOCARCINOMA; ADNEXAL DISEASES; FEMALE; GENOME, HUMAN; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; PAGET DISEASE, EXTRAMAMMARY; RECEPTOR, ERBB-2;

EID: 84906971961     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0054     Document Type: Note

References (10)

1. Dubreuilh W. Paget's disease of the vulva. Br J Dermatol 1901;13: 407-413.
2. Balducci L, Athar M, Smith GF et al. Metastatic extramammary Paget's disease: Dramatic response to combined modality treatment. J Surg Oncol 1988;38:38-44.
3. Voigt H, Bassermann R, Nathrath W. Cytoreductive combination chemotherapy for regionally advanced unresectable extramammary Paget carcinoma. Cancer 1992;70:704-708.
4. Takata M, Fujimoto A, Aoki H et al. erbB-2 Overexpression but no activation of beta-catenin gene in extramammary Paget's disease. J Invest Dermatol 1999;113:258-262.
5. Ogawa T, Nagashima Y, Wada H et al. Extramammary Paget's disease: Analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. Hum Pathol 2005;36:1273-1280.
6. Hanawa F, Inozume T, Harada K et al. A case of metastatic extramammary Paget'sdiseaserespondingtotrastuzumabpluspaclitaxelcombinationtherapy. Case Rep Dermatol 2011;3:223-227.
7. Takahagi S, Noda H, Kamegashira A et al. Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy. J Dermatol 2009;36:457-461.
8. Forbes SA, Bindal N, Bamford S et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-D950.
9. Greulich H, Kaplan B, Mertins P et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 2012;109:14476-14481.
10. Bose R, Kavuri SM, Searleman AC et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3: 224-237.